We’re using technology to help develop the COVID-19 vaccine
February 12, 2021
<<< Start >>>
<<< End >>>
One idea. One discovery. One life-changing solution. That’s all it takes to make a lasting difference in the lives of millions.
As the Client Experience Lead for the Accenture India Life Sciences R&D Operations team, we are working closely with several leading biopharma companies to develop the most-awaited preventive therapy in today’s times—the COVID-19 vaccine.
Never has there been a better time to deliver on the promise of technology and human ingenuity to improve the lives of millions worldwide.
The life support of next-gen tech
Imagine the role of technology in gaining a precise understanding of disease states and creating new paths to treatments.
Due to COVID-19, regular in-person medical appointments shifted to virtual experiences. To understand these changes in behavior, we conducted a global survey of 2,700 patients and found that as restrictions came into effect, patients faced difficulties in continuing with their treatments.
Healthcare companies can respond quickly to evolving customer needs by reimagining the patient experience. How? By harnessing the full power of intelligent operations with innovative technologies such as artificial intelligence (AI), machine learning and blockchain.
We’ve developed an end-to-end platform on Google Cloud called INTIENT. This solution helps life sciences companies advance their capabilities—from discovery and development of innovative therapies to complex treatment delivery—with incredible speed and efficacy.
As the biopharma industry explores new ways to raise the standard of patient care, INTIENT will enable information on new lines of treatment to seamlessly flow across healthcare companies and hospitals. This will provide relevant data at the right time to the right team, leading to better patient outcomes, faster than ever.
A new era of virtual patient care
Developing a vaccine is only the first step in finding a preventive cure for COVID-19. The real challenge will be in making it available to people across geographies at speed and scale. We’ve worked out a solution for that, too.
Bringing together our industry, analytics and consulting expertise, we created a comprehensive vaccine management solution. Using this solution, healthcare organizations can accelerate the development and distribution of their mass immunization programs.
I believe that, with customized patient preferences, a new era of virtual patient care has begun and is here to stay. With these shifts, we can expect to see biopharma companies increase their investment in virtual communications for enhancing patient experience.
My passion for life sciences
Life sciences has always been my calling. A lot of what I do at Accenture for improving patient care and experience, especially in these challenging times, connects back strongly with my passion to give back to society.
I earned my master’s degree in industrial management from the Indian Institute of Technology. I’m a Six Sigma Black Belt and certified project management professional. I kickstarted my career as an automation control engineer and have been with the Accenture Life Sciences Research and Development (R&D) team since 2011.
Work with impact
There’s never been a better time to be part of our diverse, innovative team of more than 3,100 professionals in Life Sciences R&D Operations at Accenture.
You’ll have the opportunity to gain unique perspectives across 13 global centers including North America, Europe, India, Japan, China and Latin America to enable personalized healthcare and help biopharma organizations create better patient experiences.
If you are looking to innovate, lead and transform life sciences to make a world of difference to millions of patients worldwide, Accenture is the place to be.
Copyright © 2021 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.
This content is provided for general information purposes and is not intended to be used in place of consultation with our professional advisors. This document refers to marks owned by third parties. All such third-party marks are the property of their respective owners. No sponsorship, endorsement or approval of this content by the owners of such marks is intended, expressed or implied.
